Document Type : Original Article(s)

Authors

• Arash Akhlaghi ¹
• Shahin Shirani ²
• Naghmeh Ziaie ³
• Omid Pirhaji ⁴
• Majid Yaran ⁵
• Golnoosh Shahverdi ⁶
• Nizal Sarrafzadegan ⁷
• Alireza khosravi ⁸
• Elham khosravi ⁹

¹ MD, Fellowship of Cardiology, Department of Cardiology, Isfahan Cardiovascular Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan

² MD, Associate Professor, Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan

³ MD, Cardiologist, Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan,

⁴ Medical Student, School of Medicine, Isfahan University of Medical Sciences, Isfahan

⁵ PhD in Clinical Laboratory, Infectious and Tropical Diseases Research Center, Isfahan University of Medical Sciences, Isfahan

⁶ Medical Student, School of Medicine, Isfahan University of Medical Sciences, Isfahan.

⁷ MD, Professor, Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan

⁸ MD, Associate Professor, Department of Cardiology, Isfahan Hypertension Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan

⁹ BSc, Laboratory Sciences, Hypertension Research Center, Isfahan Cardiovascular Research Institute, Isfahan University Of Medical Sciences, Isfahan

Abstract

BACKGROUND: The polymorphisms of cytochrome P450 2C19 (CYP2C19) gene are major prognostic factors for the response to clopidogrel therapy in patients with coronary artery diseases (CAD). The CYP2C19*2 is the most important allele responsible for resistance to clopidogrel therapy. This study examined CYP2C19 gene polymorphism (CYP2C19*1 and *2) in Iranian patients.   METHODS: This cross-sectional study was performed on 43 Iranian patients with CAD who underwent percutaneous coronary intervention (PCI) and received drug-eluted stents (DES). CYP2C19 polymorphisms were assessed using real time PCR and frequency of CYP2C19*1 and CYP2C19*2 were determined, and then homo- or heterozygous state of genes was detected by Melt Curve Analysis method.   RESULTS: Forty three patients (mean age = 58.8 ± 10.0 years, 79.1% male) participated in this study. CYP2C19*1/CYP2C19*1 genotype was observed in 31 (72.1%) of participates, CYP2C19*1/CYP2C19*2 genotype in 10 (23.3%), and CYP2C19*2/CYP2C19*2 genotype in 2 patients (4.7%). The frequency of CYP2C19*2 allele in the sample was 27.9%.   CONCLUSION: This study demonstrated a high prevalence of CYP2C19*2 gene polymorphism in Iranian patients. Further studies with larger samples or longitudinal are required to determine the effects of this polymorphism on the prognosis of CAD patients in our population.   Keywords: CYP2C19, Polymorphism, Clopidogrel, Coronary Artery Disease, Iran.